Estados financieros detallados de Jupiter Neurosciences, Inc. (JUNS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Jupiter Neurosciences, Inc. registró ingresos de $21796 en el último ejercicio fiscal, con un CAGR de 5 años del -54.6%.
Márgenes de los últimos 12 meses: margen bruto 88.3%, margen operativo -151.7%, margen neto -142.2%.
Al precio actual de $2.93, JUNS presenta beneficios negativos (P/E no significativo) y un ROE del 7.47%. La capitalización bursátil es de $1M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | $1.1M | $638037 | $233281 | 0 | 0 | $21796 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | $4231 |
| Beneficio Bruto | 0 | $1.1M | $638037 | $233281 | 0 | 0 | $17565 |
| I+D | $685741 | $1.6M | $1.4M | $942806 | $954793 | $492660 | $2.1M |
| Generales y Administrativos | $1.5M | $1.3M | $3.1M | $2.7M | $2.9M | $2.6M | $6.8M |
| Gastos Operativos | $2.2M | $3.0M | $4.5M | $3.7M | $3.9M | $3.1M | $8.9M |
| Beneficio Operativo | -$2.2M | -$1.9M | -$3.9M | -$3.4M | -$3.9M | -$3.1M | -$8.9M |
| EBITDA | -$2.7M | -$1.6M | -$4.1M | -$4.2M | -$4.6M | -$2.2M | -$8.6M |
| Gastos por Intereses | $317104 | $13535 | $113994 | $740854 | $218705 | $248366 | $66020 |
| Beneficio Antes de Impuestos | -$3.0M | -$1.7M | -$4.2M | -$5.0M | -$4.8M | -$2.4M | -$8.6M |
| Impuestos | 0 | 0 | $179168 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$3.0M | -$1.7M | -$4.4M | -$5.0M | -$4.8M | -$2.4M | -$8.6M |
| BPA | $-26.25 | $-14.25 | $-33.00 | $-11.25 | $-10.50 | $-6.36 | $-18.75 |
| BPA Diluido | $-26.25 | $-14.25 | $-33.00 | $-11.25 | $-10.50 | $-6.36 | $-18.75 |
| Acciones en Circulación (Diluidas) | $116511 | $116511 | $126489 | $438352 | $438352 | $383774 | $461715 |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | $21796 | $18652 | $24245 |
| Beneficio Bruto | 0 | $21796 | $14290 | $21064 |
| Beneficio Operativo | -$2.3M | -$2.8M | -$2.0M | -$2.7M |
| EBITDA | -$2.3M | -$2.5M | -$1.9M | -$2.7M |
| Beneficio Neto | -$2.3M | -$2.6M | -$2.1M | -$2.3M |
| BPA | $-5.25 | $-5.61 | $-4.39 | $-4.08 |
| BPA Diluido | $-5.25 | $-5.61 | $-4.39 | $-4.08 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $1276 | $207998 | $330602 | $64431 | $28478 | $3.8M | $3.8M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | $126233 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | $159790 |
| Activos Corrientes | $4968 | $549983 | $454674 | $69663 | $28739 | $4.7M | $4.8M |
| Inmovilizado Material | 0 | 0 | $208926 | $162498 | $116070 | $69642 | $23214 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $6177 | $549983 | $667383 | $235944 | $148592 | $6.2M | $5.6M |
| Cuentas por Pagar | $131051 | $252192 | $256893 | $187032 | $189495 | $278676 | $131130 |
| Deuda a Corto | $1.2M | $108479 | $440610 | $1.7M | $2.0M | $146432 | $5.3M |
| Pasivos Corrientes | $5.0M | $4.3M | $5.7M | $7.3M | $5.8M | $2.0M | $7.4M |
| Deuda a Largo | 0 | 0 | 0 | 0 | $106712 | 0 | 0 |
| Pasivos Totales | $5.0M | $4.3M | $5.8M | $7.4M | $5.9M | $2.0M | $7.4M |
| Reservas | -$8.0M | -$9.6M | -$13.8M | -$18.8M | -$23.6M | -$26.0M | -$34.7M |
| Patrimonio Neto | -$5.0M | -$3.7M | -$5.2M | -$7.1M | -$5.8M | $4.2M | -$1.8M |
| Deuda Total | $1.2M | $108479 | $651201 | $1.9M | $2.2M | $217761 | $5.3M |
| Deuda Neta | $1.2M | -$99519 | $320599 | $1.8M | $2.2M | -$3.6M | $1.5M |
| Capital Circulante | -$5.0M | -$3.7M | -$5.2M | -$7.2M | -$5.7M | $2.6M | -$2.6M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $723797 | $3.8M | $2.4M | $1.5M |
| Activos Totales | $2.6M | $5.6M | $3.9M | $3.7M |
| Pasivos Totales | $2.5M | $7.4M | $6.7M | $4.1M |
| Patrimonio Neto | $57417 | -$1.8M | -$2.8M | -$365966 |
| Deuda Total | $180393 | $5.3M | $4.8M | $1.7M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$3.0M | -$1.7M | -$4.2M | -$5.0M | -$4.8M | -$2.4M | -$8.6M |
| Amortizaciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $944577 | $563530 | $1.3M | $817251 | $1.2M | $1.8M | $2.4M |
| Cambio en Capital Circulante | $1.1M | $964128 | $781288 | $1.5M | $2.3M | -$2.6M | $105390 |
| Flujo de Caja Operativo | -$142952 | -$254783 | -$1.7M | -$1.2M | -$480953 | -$3.9M | -$5.4M |
| Inversiones (CapEx) | 0 | 0 | -$4 | $4 | $3 | $4 | -$4 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$142952 | -$254783 | -$1.7M | -$1.2M | -$480953 | -$3.9M | -$5.4M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$1.2M | -$2.4M | -$1.4M | -$2.3M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.2M | -$2.4M | -$1.4M | -$2.3M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $1.1M | -$2.0M | $500992 | $490997 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | -43.3% | -63.4% | -100.0% | | |
| Crecimiento Beneficio Neto (anual) | | +45.7% | -164.7% | -13.2% | +3.5% | +49.0% | -254.4% |
| Crecimiento BPA (anual) | | +45.7% | -131.6% | +65.9% | +6.7% | +39.4% | -194.8% |
| Cambio en Acciones (anual) | | +0.0% | +8.6% | +246.6% | +0.0% | -12.5% | +20.3% |
| Crecimiento FCF (anual) | | -78.2% | -581.0% | +28.0% | +61.5% | -713.2% | -38.4% |
| Margen Bruto | | 100.0% | 100.0% | 100.0% | | | 80.6% |
| Margen Operativo | | -164.4% | -612.4% | -1471.4% | | | -40873.2% |
| Margen EBITDA | | -145.7% | -640.4% | -1807.6% | | | -39359.9% |
| Margen Neto | | -146.9% | -686.4% | -2125.2% | | | -39662.8% |
| Margen FCF | | -22.6% | -271.9% | -535.2% | | | -24838.2% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -4.3% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-1.23 | $-2.19 | $-13.72 | $-2.85 | $-1.10 | $-10.19 | $-11.73 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $116511 | $116511 | $126489 | $438352 | $438352 | $383774 | $461715 |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 747.33% |
| Rentabilidad sobre capital invertido | -709.40% |
| Rentabilidad sobre activos | -247.39% |
| Margen bruto | 88.34% |
| Margen operativo | -15166.68% |
| Margen neto | -14220.12% |
Salud financiera
| Deuda / Patrimonio | -4.78 |
| Ratio corriente | 0.66 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -15.69 | -28.89 | -12.48 | -36.60 | -39.21 | -126.18 | -4.08 |
| P/VC | -9.56 | -12.93 | -10.06 | -25.26 | -31.11 | 73.82 | -19.28 |
| P/V | 0.00 | 42.60 | 81.63 | 773.71 | 0.00 | 0.00 | 1620.54 |
| Margen Bruto | 0.0% | 100.0% | 100.0% | 100.0% | 0.0% | 0.0% | 80.6% |
| Margen Operativo | 0.0% | -164.4% | -612.4% | -1471.4% | 0.0% | 0.0% | -40873.2% |
| Margen Neto | 0.0% | -146.9% | -686.4% | -2125.2% | 0.0% | 0.0% | -39662.8% |